Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotrovimab - GlaxoSmithKline/Vir Biotechnology

Next Previous
X
Search
Drug Profile

Sotrovimab - GlaxoSmithKline/Vir Biotechnology

Alternative Names: GSK-4182136; VIR-7831; WBP 2275; Xevudy

Latest Information Update: 04 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vir Biotechnology
  • Developer GSK; Vir Biotechnology
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 19 Sep 2024 GlaxoSmithKline and Vir Biotechnology terminates a phase I COSMIC trial for COVID-2019 infections (In volunteers), in USA (IM) due to evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes (NCT05280717)
  • 11 Oct 2023 Efficacy and safety data from a phase I COSMIC trial in COVID-2019 infections released by GlaxoSmithKline
  • 21 Jul 2023 GlaxoSmithKline and Vir Biotechnology terminates the phase II COMET-PACE trial in COVID-2019 infections (In infants, In neonates, In children, In adolescents, In adults) in the US, Brazil, Greece, Philippines, and South Africa (IM) (IV), due to decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants (NCT05124210) (EudraCT2021-003717-18)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top